- Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony will be joining the BriaCell board of directors
- Both additions have extensive experience in the biopharma industry, bringing expert knowledge in the field of clinical oncology
- Company recently announced a private placement offering that will generate proceeds for the phase IIa combination clinical trial of Bria-IMT with KEYTRUDA in advanced breast cancer
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, announced several key changes to its board of directors on March 18, 2019, as part of the company’s drive to add shareholder value and further advance its goals (http://ibn.fm/nEvKx).
The company announced the addition of new board members Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony, and three members of the BriaCell board of directors resigned. As of March 18, the board of directors members that will participate in the April 10 annual shareholders meeting include CEO William V. Williams, director and acting chairman of the board Jamieson Bondarenko and directors Charles Wiseman, Taub and Embro-Pantalony.
Taub served as a chief executive officer and currently serves as chief medical officer and executive vice president for Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), a clinical stage biopharmaceutical company developing new therapeutic approaches. Previously, she was the senior vice president, R&D, of VIA Pharmaceuticals and the vice president of Hoffman-La Roche. She oversaw clinical development and drug discovery programs.
Taub was a professor of genetics and medicine at the University of Pennsylvania, and she has authored over 120 research articles. She also served as an assistant professor at the Joslin Diabetes Center at Harvard Medical School.
Embro-Pantalony is chairman of the board with Soricimed Biopharma, a private clinical-stage biopharma company developing targeted cancer therapies. He’s also a director at Microbix Biosystems (TSX: MBX), a manufacturer of viral and bacterial antigens and reagents for the global diagnostic industry. Over the years, Embro-Pantalony has held various executive positions focused on finance, strategic planning, business development and IT.
“Both Dr. Taub and Mr. Embro-Pantalony are widely-regarded forces in the biopharma industry, bringing expert prowess in clinical oncology, corporate partnership strategy and board governance,” BriaCell’s Bondarenko said in a news release.
In addition, BriaCell Therapeutics Corp. has also announced a private placement offering to generate proceeds for the company’s phase IIa combination Bria-IMT and KEYTRUDA study (http://ibn.fm/B9vCL). Bria-IMT is BriaCell’s lead drug candidate – an immunotherapy solution for advanced breast cancer patients.
The company’s common shares will be offered at a price of C$0.10 per share for gross proceeds of approximately C$2 million. The offering is scheduled to close on or about March 28, 2019.
Notably, the securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any U.S. state securities laws. They may not be offered in the U.S.
BriaCell Therapeutics Corp. is based in Berkeley, California, and its headquarters are located in Vancouver, British Columbia. The clinical-stage biotechnology company focuses its research and development efforts on targeted immunotherapy for advanced breast cancer patients. Based on the Bria-IMT clinical trials, BriaCell is also developing Bria-OTS, a personalized off-the-shelf immunotherapy solution for advanced breast cancer patients.
For more information, visit the company’s website at www.BriaCell.com
NOTE TO INVESTORS: The latest news and updates relating to BCTXF are available in the company’s newsroom at http://ibn.fm/BCTXF